Diagnostic Criteria for Breast Cancer-Related Lymphedema of the Upper Extremity: The Need for Universal Agreement

Ann Surg Oncol. 2022 Feb;29(2):989-1002. doi: 10.1245/s10434-021-10645-3. Epub 2021 Sep 9.

Abstract

With advances in breast cancer treatments and resultant increased survival rates, emphasis has been placed on post-treatment complications such as breast cancer-related lymphedema (BCRL), a chronic, negative sequela of breast cancer treatment. Accurate BCRL diagnosis necessitates longitudinal screening beginning at preoperative baseline. Prospective screening programs incorporating symptoms, objective measurements and clinical examination allow for early detection, early intervention, and improved BCRL prognosis. Currently, varied diagnostic criteria for BCRL exist, and this lack of consensus leads to variation in diagnostic and screening practices across institutions. This review outlines current diagnostic tools, including subjective and objective measurement methods and clinical examination. The merits of different criteria are evaluated and recommendations are made regarding measurement tools and diagnostic criteria for BCRL. Ultimately, the BCRL diagnostic process should be universalized and combine objective measurements, clinical evaluation, and symptoms assessment, and adhere to the best practices of the measurement tools used.

Publication types

  • Review

MeSH terms

  • Breast Cancer Lymphedema* / diagnosis
  • Breast Cancer Lymphedema* / etiology
  • Breast Neoplasms* / complications
  • Breast Neoplasms* / diagnosis
  • Female
  • Humans
  • Lymphedema* / diagnosis
  • Lymphedema* / etiology
  • Prospective Studies
  • Upper Extremity